Floatz logo

Vorinostat

Childhood Atypical Teratoid/Rhabdoid Tumor

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Childhood Atypical Teratoid/Rhabdoid Tumor cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2B
ETOPOSIDE
Medical University of Vienna
Phase 2CCC
Thalidomide
Medical University of Vienna
Phase 2CCC
Dfn-15
Medical University of Vienna
Phase 2CCC
Irinotecan
Medical University of Vienna
Phase 2CCC

View all 39 →

Same molecule, other indications

Vorinostat is also rated in:

Non-Small-Cell Lung CarcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →